hypertension
Conditions
Interventions
Once daily of valsartan (40-160mg/day) at morning for 4 months
Once daily of valsartan (40-160mg/day) at evening for 4 months
Once daily of olmesartan medoxomil (10-40mg/day) at morning for 4 months
O
Sponsors
Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: I. Men and women aged 20 or over II. Taking once daily of valsartan (40-160 mg/day) at morning III. More than two months without any change in treatment, including valsartan IV. Need not be considered additional changes and anti-hypertensive drugs V. If any other diseases complicated, it has been either stable disease, treatment details (drug and its usage) need not be expected to change VI. Been obtained in written informed consent to participate in this study
Exclusion criteria
Exclusion criteria: I. Have an anamnesis to the drug II. Pregnant or potentially pregnant women III. Severe renal impairment (more than twice the standard value of serum creatinine, including the case in hemodialysis) IV. Have been diagnosed with secondary hypertension V. Shift workers and night workers (Have an irregular rhythm of life-style) VI.Judged inappropriate to participate in this study by a doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| # Decrease rate of nocturnal blood pressure # Change in the fall of blood pressure during night-time # Changes in urine albumin level and serum cystatin C concentration | — |
Countries
Japan
Contacts
Public ContactKentaro Ushijima
Jichi Medical University Clinical Pharmacology
Outcome results
None listed